Compare Appian Corp (APPN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Johnson & Johnson — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 246.5× Appian Corp's market cap, and Johnson & Johnson pays a 2.06% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | JNJ | |
|---|---|---|
Market Cap | $2.54B | $626.09B |
Sector | Technology | Health |
52-Week High | $45.64 | $267.24 |
52-Week Low | $18.72 | $172.78 |
Enterprise Value | $2.67B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.82, down 2.14% on the day despite strong technical momentum. The stock shows bullish moving average signals but overbought RSI readings. Fundamentally, the company delivered three consecutive earnings beats with Q2 2026 EPS of $0.13 beating expectations of $0.00308, while revenue grew 19% year-over-year to $203.3 million. Recent news highlights AI-powered underwriting partnerships and strong enterprise demand driving growth.
Appian presents a mixed investment case with strong revenue growth and AI momentum offset by negative profitability metrics and elevated valuations. The stock trades above analyst consensus target of $32.50, suggesting limited near-term upside. Key risks include persistent negative ROE (-936.62%) and high debt levels, though improving cash flow and AI adoption provide growth catalysts.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
